Innovation in Cancer Research


Tom Lynch, Chief Scientific Officer, Bristol-Myers Squibb

Bristol-Myers Squibb Validates Predictive Role of Tumor Mutation Burden in Phase 3 CheckMate -227 Program in First-Line Non-Small Cell Lung Cancer

The Evolution of  CheckMate -227

The Evolution of  CheckMate -227

Learn more about our Phase 3 program, CheckMate -227.

Media Resources

Scientific Media Resources
Find more information about immune biomarkers, our translational approach and oncology pipeline. 

Media Contacts

Information for the media and journalists